These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Guerrero C; Puig N; Cedena MT; Goicoechea I; Perez C; Garcés JJ; Botta C; Calasanz MJ; Gutierrez NC; Martin-Ramos ML; Oriol A; Rios R; Hernandez MT; Martinez-Martinez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Mosquera-Orgueira A; Gonzalez-Perez MS; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B Clin Cancer Res; 2022 Jun; 28(12):2598-2609. PubMed ID: 35063966 [TBL] [Abstract][Full Text] [Related]
3. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Suzuki K Int J Hematol; 2020 Apr; 111(4):512-518. PubMed ID: 32125606 [TBL] [Abstract][Full Text] [Related]
4. Potential future direction of measurable residual disease evaluation in multiple myeloma. Mohty M; Avet-Loiseau H; Malard F; Harousseau JL Blood; 2023 Nov; 142(18):1509-1517. PubMed ID: 37471603 [TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. Berger N; Kim-Schulze S; Parekh S Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265 [TBL] [Abstract][Full Text] [Related]
6. Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. D'Agostino M; Bertamini L; Oliva S; Boccadoro M; Gay F Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847174 [TBL] [Abstract][Full Text] [Related]
7. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma? Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555520 [TBL] [Abstract][Full Text] [Related]
8. Is molecular remission the goal of multiple myeloma therapy? Davies FE Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):205-211. PubMed ID: 29222257 [TBL] [Abstract][Full Text] [Related]
9. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Landgren O; Lu SX; Hultcrantz M Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154 [TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye. Vaxman I; Gertz MA Leuk Lymphoma; 2021 Jul; 62(7):1544-1553. PubMed ID: 33508994 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422 [TBL] [Abstract][Full Text] [Related]
12. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Kunacheewa C; Lee HC; Patel K; Thomas S; Amini B; Srour S; Bashir Q; Nieto Y; Qazilbash MH; Weber DM; Feng L; Orlowski RZ; Lin P; Manasanch EE Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e221-e238. PubMed ID: 32037287 [TBL] [Abstract][Full Text] [Related]
13. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review]. Yu Q; Shi JM; Tao Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668 [TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Waldschmidt JM; Anand P; Knoechel B; Lohr JG Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150 [TBL] [Abstract][Full Text] [Related]
16. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315 [TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567 [TBL] [Abstract][Full Text] [Related]
20. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022 [No Abstract] [Full Text] [Related] [Next] [New Search]